Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Published

Journal Article

BACKGROUND: TAFI is a plasma protein assumed to be an important link between coagulation and fibrinolysis. The three-dimensional crystal structures of authentic mature bovine TAFI (TAFIa) in complex with tick carboxypeptidase inhibitor, authentic full lenght bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI), and recombinant human TAFI have recently been solved. In light of these recent advances, we have characterized authentic bovine TAFI biochemically and compared it to human TAFI. RESULTS: The four N-linked glycosylation sequons within the activation peptide were all occupied in bovine TAFI, similar to human TAFI, while the sequon located within the enzyme moiety of the bovine protein was non-glycosylated. The enzymatic stability and the kinetic constants of TAFIa differed somewhat between the two proteins, as did the isoelectric point of TAFI, but not TAFIa. Equivalent to human TAFI, bovine TAFI was a substrate for transglutaminases and could be proteolytically cleaved by trypsin or thrombin/solulin complex, although small differences in the fragmentation patterns were observed. Furthermore, bovine TAFI exhibited intrinsic activity and TAFIa attenuated tPA-mediated fibrinolysis similar to the human protein. CONCLUSION: The findings presented here suggest that the properties of these two orthologous proteins are similar and that conclusions reached using the bovine TAFI may be extrapolated to the human protein.

Full Text

Cited Authors

  • Valnickova, Z; Thaysen-Andersen, M; Højrup, P; Christensen, T; Sanggaard, KW; Kristensen, T; Enghild, JJ

Published Date

  • January 2009

Published In

Volume / Issue

  • 10 /

Start / End Page

  • 13 -

PubMed ID

  • 19416536

Pubmed Central ID

  • 19416536

Electronic International Standard Serial Number (EISSN)

  • 1471-2091

International Standard Serial Number (ISSN)

  • 1471-2091

Digital Object Identifier (DOI)

  • 10.1186/1471-2091-10-13

Language

  • eng